ArticleHaematologica2010
CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases.
Article in Haematologica, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03712488 (Differential Expression of CD200 in B-chronic Lymphoproliferative Disorders by Multicolour Flow Cytometry), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Differential Expression of CD200 in B-chronic Lymphoproliferative Disorders by Multicolour Flow Cytometry
Who cites it
20 citing papers in PubMed, 97 citations in OpenAlex.
- Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients.International journal of cancer · 2018Trial
- Review
- CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas.Blood neoplasia · 2024Article
- Splenic marginal zone lymphoma with prolymphocytic transformation and cyclin D1 expression in the absence of CCND1 rearrangement.International journal of hematology · 2024Review
- Article
- The many faces of nodal and splenic marginal zone lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop.Virchows Archiv : an international journal of pathology · 2023Review
- CD5-Negative, CD10-Negative Low-Grade B-Cell Lymphoproliferative Disorders of the Spleen.Current oncology (Toronto, Ont.) · 2021Review
- How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen.Current oncology (Toronto, Ont.) · 2021Review
- New Insights into the Biology and Diagnosis of Splenic Marginal Zone Lymphomas.Current oncology (Toronto, Ont.) · 2021Review
- Diagnostic challenges in an aggressive case of peripheralizing marginal zone lymphoma.Clinical case reports · 2020Article
- Prognostic significance of aberrant CD5 expression in B-cell leukemia.Oncology reviews · 2019Article
- Surgical management of splenic marginal zone lymphoma.Irish journal of medical science · 2018Article
- Exome sequencing identifies recurrentHaematologica · 2017Article
- Ageing of the B-cell repertoire.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2015Article
- CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2015Article
- Successful Treatment of Leukemic Mature B-Cell Lymphoid Neoplasm with Similar Features to Splenic Marginal Zone Lymphoma Possessing Aberrant Myeloid Markers.Case reports in hematology · 2015Article
- Utility of quantitative flow cytometry immunophenotypic analysis of CD5 expression in small B-cell neoplasms.Archives of pathology & laboratory medicine · 2014Article
- Cell-surface expression of the TLR homolog CD180 in circulating cells from splenic and nodal marginal zone lymphomas.Leukemia · 2013Article
- Article
- Splenic marginal zone lymphoma: hydra with many heads?Haematologica · 2010Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClassically, splenic marginal zone B-cell lymphoma is characterized by the absence of CD5 expression. Cases of apparent splenic marginal zone B-cell lymphoma showing CD5 expression, as diagnosed by blood studies, have been described; however, in the absence of histological evidence, the correct diagnosis of these cases is controversial because of possible confusion with other CD5-positive small B-cell neoplasms. DESIGN AND
methodsWe report a series of 24 CD5-positive, t(11;14)-negative cases of splenic marginal zone B-cell lymphoma diagnosed by flow cytometry studies of blood and histologically proven on spleen sections. Clinical data as well as morphological, immunological, cytogenetic and molecular characteristics were assessed to evaluate the similarities and differences of these cases with those of classical CD5-negative splenic marginal zone B-cell lymphoma.
resultsThe CD5 expression detected in blood by flow cytometry was confirmed in most cases by immunohistochemistry on spleen sections. In general, cases of CD5-positive and CD5-negative splenic marginal zone B-cell lymphoma did not appear different and, in particular, they showed similar karyotypic changes such as 7q deletion, trisomy 3, trisomy 18 and biased IGHV usage (i.e. VH1-2). The main differences were a higher lymphocyte count at diagnosis (8.15x10(9)/L versus 3.90x10(9)/L; P=0.005) and more frequent diffuse bone marrow infiltration (34% versus 8%; P=0.03) in the CD5-positive group. A tendency to a more mutated IGHV status in the CD5 positive cases was observed (80% versus 54.5%; (P=0.11). No significant differences in outcome were found in relation to CD5 expression.
conclusionsThis study confirms the existence of cases of CD5-positive splenic marginal zone B-cell lymphoma and shows that these cases are closely related to classical splenic marginal zone lymphoma. Whether or not CD5-positive splenic marginal zone B-cell lymphoma constitutes a true subset obviously requires the study of more cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.